Business Context and Reporting Period
This Form 8-K Current Report was filed by Digital Ally, Inc. (trading symbol: DGLY) on February 18, 2025, reporting events occurring between February 13 and February 14, 2025. The filing details the entry into a material definitive agreement for a public equity offering and the subsequent closing of that offering.
Key Financial Metrics and Transaction Details
- Net Proceeds: Approximately $13.48 million after deducting underwriting fees and offering expenses.
- Offering Structure:
- Units: 7,850,000 units sold at $0.15 per unit. Each unit includes one share of Common Stock, one Series A Warrant (exercise price $0.1875), and one Series B Warrant (exercise price $0.30).
- Pre-Funded Units: 92,150,000 pre-funded units sold at $0.149 per unit. Each includes a pre-funded warrant (exercise price $0.001), one Series A Warrant, and one Series B Warrant.
- Over-Allotment: The underwriter exercised an option to purchase an additional 15,000,000 Series A Warrants and 15,000,000 Series B Warrants on February 14, 2025.
- Underwriting Fees: Aegis Capital Corp. received 7% of the aggregate purchase price, a 1% non-accountable expense, and reimbursement of legal fees.
Material Changes and Use of Proceeds
The primary material change is the significant increase in liquidity through the equity offering. The Company intends to utilize the net proceeds for the following specific purposes:
- Working capital and general corporate purposes.
- Repayment of amounts owed under a short-term merchant advance.
- Full repayment of the aggregate face value of senior secured promissory notes issued in a private placement on November 6, 2024.
Guidance, Risks, and Contingencies
Warrant Exercise Contingency: The Series A and Series B Warrants are not immediately exercisable. They may only be exercised upon receipt of stockholder approval ("Warrant Stockholder Approval") for the warrant terms and the issuance of underlying shares, as required by Nasdaq rules. Additionally, an amendment to the Articles of Incorporation to increase authorized share capital may be required.
Exercise Periods:
- Series A Warrants: Exercisable from the approval date until five years thereafter.
- Series B Warrants: Exercisable from the approval date until two and one-half years thereafter.
Over-Allotment Option: The underwriter retains the option to purchase up to 15% of the shares and warrants sold in the offering within 45 days of the final prospectus date. While the warrant portion was exercised, the share portion of the over-allotment option remains available.
Investor Verification Checklist
- Verify the status of the required stockholder vote to approve the warrant terms and share issuance.
- Confirm the exact amount of debt retired from the November 2024 private placement and the short-term merchant advance.
- Monitor the exercise of the remaining over-allotment option for Common Stock shares (not just warrants).
- Review the full text of the Underwriting Agreement (Exhibit 10.1) and Warrant forms (Exhibits 4.1, 4.2, 4.3) for specific redemption or anti-dilution provisions.